SCHEMBL26648243

SCHEMBL26648243

CC(C)(C)OC(=O)c1ccc(N2CCC(C(O[Si](C)(C)C(C)(C)C)c3cc(Br)ccc3-c3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35
GPR119 Q8TDV5 3/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 2/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
ALOX5 P09917 1/20 0.33
LMNA P02545 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
BCL2 P10415 5/20 0.33
BCL2L1 Q07817 5/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
ESRRB O95718 1/20 0.32
ESR1 P03372 1/20 0.32
ESRRA P11474 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31451035 0.91 MEN1 (0.35) CNR1CNR2GPR119HTTSMN1; SMN2
SCHEMBL26647739 0.91 MEN1 (0.35) CNR1CNR2GPR119HTTSMN1; SMN2
SCHEMBL26648275 0.86 BCL2L1 (0.38) CNR1CNR2GPR119HTTSMN1; SMN2
SCHEMBL26647936 0.85 MAPT (0.39) HTTSMN1; SMN2TP53MAPTTHRB
SCHEMBL26647941 0.85 MAPT (0.39) HTTSMN1; SMN2TP53MAPTTHRB
SCHEMBL26648660 0.85 MAPT (0.39) HTTSMN1; SMN2TP53MAPTTHRB
SCHEMBL26648402 0.84 TP53 (0.32) NPSR1TP53BCL2BCL2L1MEN1
SCHEMBL31450944 0.83 F10 (0.40) SMN1; SMN2TP53MAPTTHRBKDM4E
SCHEMBL31450576 0.83 F10 (0.40) SMN1; SMN2TP53MAPTTHRBKDM4E
SCHEMBL31450817 0.83 F10 (0.40) SMN1; SMN2TP53MAPTTHRBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522154-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-03-19 EP disclosed
WO-2023220425-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed